Association of TPO Gene (rs 2048722) Polymorphisms and Serum Level of Thyroid Hormones with Papillary Thyroid Cancer

Ayaat Abbas Abdulsada; Hadeel Jabbar Neama

doi:10.54133/ajms.v6i2.781

Authors

Ayaat Abbas Abdulsada Department of Medical Biotechnology, College of Biotechnology, Al-Qadisiyah University, Diwaniyah, Iraq https://orcid.org/0009-0001-5947-1558
Hadeel Jabbar Neama Department of Medical Biotechnology, College of Biotechnology, Al-Qadisiyah University, Al-Qadisiyah, Iraq https://orcid.org/0000-0002-7236-4554

DOI:

https://doi.org/10.54133/ajms.v6i2.781

Keywords:

Papillary thyroid carcinoma, Risk factor, rs 2048722, TPO

Abstract

Background: Papillary thyroid carcinoma (PTC) is the most prevalent form of thyroid cancer, making up about 80% of cases. It is influenced by both genetic and environmental factors, making it the most prevalent form of thyroid cancer. Objective: Determine the connection between PTC and polymorphisms in the thyroid peroxidase gene (TPO, rs2048722) as a risk factor, as well as the changes in thyroid hormone serum levels. Methods: The study involved 52 PTC patients and 48 healthy controls. We looked into the link between a type of TPO polymorphism and the risk of getting PTC by finding and genotyping TPO (rs2048722) C/T in healthy people and people who had PTC using T-ARMS-PCR and checking thyroid hormone levels in the Al-Diwaniyah Governorate. Results: The polymorphism TPO (rs2048722) increased the PTC risk. According to multiple genetic models, homozygous TT genotypes increased the risk of PTC in the test by 4.03 times relative to other genotypes, and a heterozygous C/T genotype increased the risk by 2.09 times. Patients with PTC have elevated TSH. Patients over 50 exhibited greater mean values than the control group. In addition, T3 and T4 blood levels dropped significantly and increased overall. Compared to other groups, patients aged 50 and older had lower mean T3 levels. Conclusions: In the Al-Diwaniyah Governorate, there was strong evidence that the TPO rs2048722 polymorphism was linked to a higher risk of PTC. This risk was affected by age, gender, and serum thyroid hormone levels.

Downloads

Download data is not yet available.

References

Liao M, Wang Z, Yao J, Xing H, Hao Y, Qiu B. Identification of potential biomarkers for papillary thyroid carcinoma by comprehensive bioinformatics analysis. Mol Cell Biochem. 2023;478:2111-2123. doi: 10.1007/s11010-022-04606-x.

Fridman MV, Savva NN, Krasko OV, Zborovskaya AA, Mankovskaya SV, Schmid KW, et al. Clinical and pathologic features of “sporadic” papillary thyroid carcinoma registered in the years 2005 to 2008 in children and adolescents of Belarus. Thyroid. 2012;22:1016-1024. doi: 10.1089/thy.2011.0005.

Schonfeld SJ, Morton LM, Berrington de González A, Curtis RE, Kitahara CM. Risk of second primary papillary thyroid cancer among adult cancer survivors in the United States, 2000-2015. Cancer Epidemiol. 2020;64:101664. doi: 10.1016/j.canep.2019.101664.

Figge J, (Editor), Epidemiology of thyroid cancer. Thyroid Cancer: A Comprehensive Guide to Clinical Management, (2nd ed.), New York, NY: Springer; 2006.

Jing L, Zhang Q. Intrathyroidal feedforward and feedback network regulating thyroid hormone synthesis and secretion. Front Endocrinol. 2022;13. doi: 10.3389/fendo.2022.992883.

Nunez J, Pommier J. Formation of thyroid hormones. Vitamins Hormones. 1982;39:175-229. doi: 10.1016/S0083-6729(08)61137-1.

Ris-Stalpers C, Bikker H. Genetics and phenomics of hypothyroidism and goiter due to TPO mutations. Mol Cell Endocrinol. 2010;322(1-2):38-43. doi: 10.1016/j.mce.2010.02.008.

Naqvi SF, Yıldız-Bölükbaşı E, Afzal M, Nalbant G, Mumtaz S, Tolun A, et al. Homozygous mutations in thyroid peroxidase (TPO) in hypothyroidism with intellectual disability, developmental delay, and hearing and ocular anomalies in two families: Severe manifestation of untreated TPO-deficiency poses a diagnostic dilemma. Yale J Biol Med. 2023;96:347-356. doi: 10.59249%2FSSRG6507.

Mussazhanova Z, Rogounovitch TI, Saenko VA, Krykpayeva A, Espenbetova M, Azizov B, et al. The contribution of genetic variants to the risk of papillary thyroid carcinoma in the Kazakh population: Study of common single nucleotide polymorphisms and their clinicopathological correlations. Front Endocrinol (Lausanne). 2021;11:543500. doi: 10.3389/fendo.2020.543500.

Shen Z, Sun Y, Niu G. Variants in TPO rs2048722, PTCSC2 rs925489 and SEMA4G rs4919510 affect thyroid carcinoma susceptibility risk. BMC Med Genomics. 2023;16:19. doi: 10.1186/s12920-023-01447-5.

Díez JJ, Anda E, Alcazar V, Isidro ML, Familiar C, Paja M, et al. Differentiated thyroid carcinoma in the elderly: influence of age on disease-free and overall survival. Endocrine. 2022;77:121-133. doi: 10.1007/s12020-022-03059-y.

Higa GM, Fell RG. Sex Hormone receptor repertoire in breast cancer. Int J Breast Cancer. 2013;2013:284036. doi: 10.1155/2013/284036.

Lorenz K, Schneider R, Elwerr M. Thyroid carcinoma: Do we need to treat men and women differently? Visc Med. 2020;36:10-14. doi: 10.1159/000505496.

Jamshidi M, Farnoosh G, Mohammadi Pour S, Rafiee F, Saeedi Boroujeni A, Mahmoudian-Sani MR. Genetic variants and risk of thyroid cancer among Iranian patients. Horm Mol Biol Clin Investig. 2021;42(2):223-234. doi: 10.1515/hmbci-2020-0051.

Yao R, Chiu CG, Strugnell SS, Gill S, Wiseman SM. Gender differences in thyroid cancer: a critical review. Expert Rev Endocrinol Metab. 2011;6:215-143. doi: 10.1586/eem.11.9.

Denaro N, Romanò R, Alfieri S, Dolci A, Licitra L, Nuzzolese I, et al. The tumor microenvironment and the estrogen loop in thyroid cancer. Cancers. 2023;15. doi: 10.3390/cancers15092458.

Krashin E, Piekiełko-Witkowska A, Ellis M, Ashur-Fabian O. Thyroid hormones and cancer: A comprehensive review of preclinical and clinical studies. Front Endocrinol. 2019;10. doi: 10.3389/fendo.2019.00059.

Sun J, Liu J, Wu T, Gu Z, Zhang X. Sensitivity to thyroid hormone indices are associated with papillary thyroid carcinoma in Chinese patients with thyroid nodules. BMC Endocr Disord. 2023;23:126. doi: 10.1186/s12902-023-01381-8.

Gillis A, Zheng-Pywell R, McLeod C, Wang D, Ness JM, Guenter R, et al. Somatostatin receptor type 2 and thyroid-stimulating hormone receptor expression in oncocytic thyroid neoplasms: Implications for prognosis and treatment. Mod Pathol. 2023;36:100332. doi: 10.1016/j.modpat.2023.100332.

Demircioglu ZG, Demircioglu MK, Aygun N, Akgun IE, Unlu MT, Kostek M, et al. Relationship between thyroid-stimulating hormone level and aggressive pathological features of papillary thyroid cancer. Med Bull Sisli Etfal Hosp. 2022;56:126.

Lohse MJ, Bock A, Zaccolo M. G protein–coupled receptor signaling: New insights define cellular nanodomains. Annu Rev Pharmacol Toxicol. 2024;64:387-415. doi: 10.1146/annurev-pharmtox-040623-115054.

Sai Kumar BAA. Hormonal regulation of metabolism, water, and minerals. In: Das PK, Sejian V, Mukherjee J, Banerjee D, (Eds.), Veterinary Physiology, Singapore: Springer Nature Singapore; 2023, p. 391-415. doi: 10.1007/978-981-19-9410-4_16.

Grani G, Ramundo V, Verrienti A, Sponziello M, Durante C. Thyroid hormone therapy in differentiated thyroid cancer. Endocrine. 2019;66:43-50. doi: 10.1007/s12020-019-02051-3.

Haymart MR, Glinberg SL, Liu J, Sippel RS, Jaume JC, Chen H. Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol (Oxford). 2009;71:434-439. doi: 10.1111/j.1365-2265.2008.03489.x.

Zhang X, Tian L, Teng D, Teng W. The relationship between thyrotropin serum concentrations and thyroid carcinoma. Cancers. 2023;15. doi: 10.3390/cancers15205017.

Huang J, Zhao J. Quantitative diagnosis progress of ultrasound imaging technology in thyroid diffuse diseases. Diagnostics. 2023;13. doi: 10.3390/diagnostics13040700.

Yao J, Zhao J, Liu J, Jiang S, Guo S, Xu L, et al. The relationships between thyroid functions of short-term rapid hypothyroidism and blood lipid levels in post-thyroidectomy patients of differentiated thyroid cancer. Front Endocrinol. 2023;14. doi: 10.59249/ssrg6507.

Cipollini M, Pastor S, Gemignani F, Castell J, Garritano S, Bonotti A, et al. TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations. Int J Cancer. 2013;133:2843-2851. doi: 10.1002/ijc.28317.